# FORMULA-509 (NCT03141671)

> Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

No report yet. It can be ordered.

- Drugs tested: abiraterone plus apalutamide
- Indication: prostate cancer with rising PSA after radical prostatectomy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03141671
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Prostate Cancer
- Interventions: GnRH; Bicalutamide; Salvage radiation; Abiraterone; Prednisone; Apalutamide
- Enrollment: 345
- Primary outcome: PSA Progression Free Survival

## Indexed commentary on FORMULA-509 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 58 posts on X
- 15 podcast episodes
- 8 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=formula-509-nct03141671

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03141671", "email": "<work email>"}; the inbox owner confirms by the emailed link.